Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric Futures Bounce Back Owing To Short Covering

09-May2011

Turmeric Futures Bounce Back Owing To Short Covering

Turmeric futures shot in trade owing to the short covering by the investors at technically oversold zone. However, the reports of higher produce of turmeric restricted the commodity gains. As per trade sources, turmeric production in 2011 is estimated around 65 lakh bags against 45-48 lakh bags last year (Each bag=70Kg).

The contract for May delivery was trading at Rs 8524.00, up by 0.64% or Rs 54.00 from its previous closing of Rs 8470.00. The open interest of the contract stood at 12185 lots.

The contract for June delivery was at Rs 8400.00., up by 0.46% or Rs 54.00 from its previous closing of Rs 8354.00. The open interest of the contract stood at 7170 lots on NCDEX.

Related News

View all news

BT Cotton Seeds Businesses Targeting Earnings Of Rs 700 Crore This Season

BT Cotton seeds organizations are targeting earnings of Rs 700 cr this season as a result of a rise ......

Gold Challenges To Maintain Earlier Increases As The Problems In Europe Prolongs

Gold prices surrounded reduce on Monday because the euro solved their deficits in opposition to the ......

Copper Seems To Lengthen Uptrend As Dollar Recoils

Copper rates were able to lengthen the uptrend for 3rd instantly period on Monday, as traders proved......

Top News

View all news

Karnataka Bank launches CASA campaign

Karnataka Bank has launched Current & Savings Accounts campaign (CASA) of FY 2018-19 and introduced a new SB scheme 'KBL SB - TASC' a specialized product for Trusts/Associates/Societies/Clubs.Under......

M&M's arm opens manufacturing hub in Bengaluru

Mahindra & Mahindra's (M&M) subsidiary -- Mahindra Electric Mobility has opened its electric technology manufacturing hub set up with an investment of Rs 100 crore in Bengaluru. The plant......

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific......